Theriva Biologics Q2 2023: $34.2M cash, VCN-01 trial on track, FDA orphan drug

Theriva Biologics, Inc.

Cash and equivalents $34.2M as of June 30, 2023, expected runway into Q4 2024.
VIRAGE Phase 2b trial (VCN-01 + chemo) enrollment on track to complete Q1 2024; US sites dosing initiated.
FDA granted orphan drug designation to VCN-01 for pancreatic cancer; previously for retinoblastoma.
Ramon Alemany, Ph.D., appointed SVP of Discovery; continues as chair of Scientific Advisory Board.
G&A expenses rose 80% to $2.7M; R&D expenses fell 10% to $3.1M vs Q2 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Theriva Biologics, Inc. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended June 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-088628

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.